

The incidence of haematological malignancies during pregnancy ranges from 4·0 to 15·8 cases per 100 000 pregnancies, with Hodgkin lymphoma, acute leukaemia, and aggressive B-cell non-Hodgkin lymphoma being the most frequent subtypes. Although survival rates are similar to those in patients who are not pregnant with similar disease profiles, pregnant women face higher risks of maternal morbidity, along with adverse obstetric and neonatal outcomes. Their management, therefore, requires a carefully balanced approach that minimises obstetric risks and ensures effective oncological control.
Haematology
|15th Jan, 2026
|The Lancet
Haematology
|15th Jan, 2026
|The Lancet
Haematology
|15th Jan, 2026
|The Lancet
Haematology
|15th Jan, 2026
|The Lancet
Haematology
|15th Jan, 2026
|The Lancet
Haematology
|15th Jan, 2026
|The Lancet
Haematology
|15th Jan, 2026
|The Lancet